SLC6A3 and Behcet disease: Notably, pharmaceutical therapies for BD, including N-acetylcysteine and lithium, may protect against OS and DA toxicity [171,172,173], pointing to the possibility of preventing the vicious cycle of DA inhibiting the DAT [91].